Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector

Franco Venanzi, Victor Shifrin, Michael Y. Sherman, Vladimir Gabai, Oleg Kiselev, Andrey Komissarov, Mikhail Grudinin, Maria Shartukova, Ekaterina A. Romanovskaya-Romanko, Yuri Kudryavets, Natalya Bezdenezhnykh, Oleksandra Lykhova, Nadiia Semesyuk, Antonio Concetti, Anatoly Tsyb, Marina Filimonova, Victoria Makarchuk, Raisa Yakubovsky, Andrey Chursov, Vita ShcherbininaAlexander Shneider

Research output: Contribution to journalArticlepeer-review


Autophagy plays an important role in neoplastic transformation of cells and in resistance of cancer cells to radio- and chemotherapy. p62 (SQSTM1) is a key component of autophagic machinery which is also involved in signal transduction. Although recent empirical observations demonstrated that p62 is overexpressed in variety of human tumors, a mechanism of p62 overexpression is not known. Here we report that the transformation of normal human mammary epithelial cells with diverse oncogenes (RAS, PIK3CA and Her2) causes marked accumulation of p62. Based on this result, we hypothesized that p62 may be a feasible candidate to be an anticancer DNA vaccine. Here we performed a preclinical study of a novel DNA vaccine encoding p62. Intramuscularly administered p62-encoding plasmid induced anti-p62 antibodies and exhibited strong antitumor activity in four models of allogeneic mouse tumors - B16 melanoma, Lewis lung carcinoma (LLC), S37 sarcoma, and Ca755 breast carcinoma. In mice challenged with Ca755 cells, p62 treatment had dual effect: inhibited tumor growth in some mice and prolonged life in those mice which developed tumor size similar to control. P62-encoding plasmid has demonstrated its potency both as a preventive and therapeutic vaccine. Importantly, p62 vaccination drastically suppressed metastasis formation: in B16 melanoma where tumor cells where injected intravenously, and in LLC and S37 sarcoma with spontaneous metastasis. Overall, we conclude that a p62-encoding vector(s) constitute(s) a novel, effective broadspectrum antitumor and anti-metastatic vaccine feasible for further development and clinical trials.

Original languageEnglish
Pages (from-to)1829-1835
Number of pages7
Issue number10
StatePublished - Oct 2013
Externally publishedYes


  • Autophagy
  • Cancer immunotherapy
  • DNA vaccine
  • Metastases

All Science Journal Classification (ASJC) codes

  • Oncology


Dive into the research topics of 'Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector'. Together they form a unique fingerprint.

Cite this